Toronto, August 18, 2016 – Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring.
This announcement was covered in Yahoo Finance, The Canadian Business Journal, Global News Wire, and BioSpace.
Applied immediately after surgical wound closure, SCX-001 reduces the amount of scar tissue that develops during the body’s natural healing process. The 24-subject Phase I clinical trial will be conducted at ...
Partnership expected to revolutionize the supply of transplantable lungs, with market launch in Europe by XENiOS® expected in 2017
HEILBRONN, Germany and TORONTO, Canada — XENiOS®, a commercial-stage medical device company, announced today it has invested $2.6 million in XOR-Labs Toronto (“XOR”), a spin-off of Toronto General Hospital at University Health Network (UHN), the world’s leading center for lung transplantation, created in partnership with MaRS Innovation.
This announcement was covered in FierceMedicalDevices and Cystic Fibrosis News Today.
VICE featured XOR's life-saving lung transplant technology ...
TORONTO and SAN DIEGO (September 25, 2015) — Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase 2 proof-of-concept, today announced that it has received approval from Health Canada to initiate its Phase 1 clinical study of marizomib in combination with bevacizumab (Avastin®) in patients with recurrent malignant glioma in Canada. Marizomib is a novel and highly potent proteasome inhibitor that readily penetrates the blood brain barrier. It prevents the breakdown of proteins involved in signal ...
This op-ed on Canadian biotechnology and the knowledge economy appeared in The Hill-Times (subscription required), Canada's politics and government newsweekly, September 9:
Obesity, cancer, heart disease and stroke, diabetes, Parkinson’s disease, Alzheimer’s, or the more general stresses of an aging population: no matter which area of concern holds our collective gaze from moment to moment, improving health outcomes and healthcare is the No. 1 challenge for the world’s economy.
Canada has the holistic approach and translational research necessary to address health care’s pervasive ...
September 9, 2013
in Baycrest Centre for Geriatric Care, Centre for Addiction and Mental Health (CAMH), DLVR Therapeutics Inc, Encycle Therapeutics, Holland Bloorview Kids Rehabilitation Hospital, Kapplex, Licenseable Technologies, MaRS Discovery District, Media Coverage, Member Institutions, News, Partnerships, Portfolio, Ryerson University, Sinai Health, St. Michael's Hospital, Start-Up Companies, Sunnybrook Health Sciences Centre, The Hospital for Sick Children (SickKids), The Ontario Institute for Cancer Research (OICR), TIAP Staff, University Health Network, University of Toronto, Women's College Hospital, Xagenic, York University
Networks of Centres of Excellence recognizes strength of partnership between MI and its 16 member institutions
TORONTO, February 5, 2013 — How do you make sure the brilliant ideas emerging from Toronto’s academic research community get the best possible chance to succeed?
MaRS Innovation (MI), created in 2008, bridges the chasm between these early-stage technologies and successful start-up companies and licensable technologies. By offering early-stage funding in tandem with hands-on management, mentorship and IP strategy protection, MI acts as a commercialization agent for ...
February 6, 2013
in Awards, Baycrest Centre for Geriatric Care, Centre for Addiction and Mental Health (CAMH), Funding or Fundraising-Announcements, Government Partners, Holland Bloorview Kids Rehabilitation Hospital, Industry Partners, Licenseable Technologies, MaRS Discovery District, Member Institutions, News, Partnerships, Portfolio, Ryerson University, Sinai Health, St. Michael's Hospital, Start-Up Companies, Sunnybrook Health Sciences Centre, The Hospital for Sick Children (SickKids), The Ontario Institute for Cancer Research (OICR), Thunder Bay Regional Research Institute (TBRRI), TIAP Staff, University Health Network, University of Toronto, Women's College Hospital, York University